Trastuzumab deruxtecan + Bevacizumab
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Conditions
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Trial Timeline
Feb 18, 2024 → Apr 1, 2027
NCT ID
NCT06271837About Trastuzumab deruxtecan + Bevacizumab
Trastuzumab deruxtecan + Bevacizumab is a phase 2 stage product being developed by Daiichi Sankyo for Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06271837. Target conditions include Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer).
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06819007 | Phase 3 | Recruiting |
| NCT06271837 | Phase 2 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)